EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial

Zhiqiang Song iD, Xiuli Zuo iD, Zhenyu Zhang iD, Xuehong Wang, Ya Lin, Yueyue Li iD, Xiaojun Xu, Yun Huang, Qiuyan Wang, Yanyan Shi, Liya Zhou iD

Helicobacter · 2025

DOI: 10.1111/hel.70070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Zhiqiang Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Amoxicillin, Pyrroles, Sulfonamides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Key laboratory for Helicobacter pylori infection and upper gastrointestinal diseases in Beijing, Takeda Pharmaceutical Company Limited, Osaka, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal duration for vonoprazan and amoxicillin dual therapy (VA‐DT) remains unclear, and studies on gastric acid suppression of vonoprazan during eradication are still lacking.

Objective

This study conducted a multicenter, randomized controlled trial to compare the eradication efficacy between 10 and 14‐day VA‐DT, and to identify the dynamic changes of gastric pH during treatment.

Methods

This study included 418 naïve adult patients with Helicobacter pylori infection, who were randomly divided into 10 or 14‐day VA‐DT groups (vonoprazan 20 mg twice daily and amoxicillin 1000 mg thrice daily). 13 C‐urea breath tests were conducted at 4–8 weeks after eradication to evaluate the success of treatment. 24‐h intragastric pH was monitored in 22 patients.

Results

Ten and 14‐day VA‐DT demonstrated eradication rates of 83.3% vs. 88.0% (rate difference: −4.8%, 95% confidence interval: −11.6% to −2.0%) in intention‐to‐treat analysis, 87.9% vs. 93.9% (−6.0%, −11.9% to −0.3%) in modified intention‐to‐treat analysis, and 89.1% vs. 95.3% (−6.1%, −11.8% to −0.7%) in per‐protocol analysis, respectively. Vonoprazan showed excellent gastric acid suppression during eradication, with the time percentages of pH > 6 at 75.3% and 97.2% and the median pH levels at 7.4 and 7.8 on the 1st and 7th days, respectively. Furthermore, gastric pH exceeded 6 approximately 4–5 h after the first dose and remained stable at 7–9 thereafter.

Conclusion

The noninferiority of eradication efficacy between 10‐ and 14‐day VA‐DT in the first‐line treatment was not established, indicating that 10‐day therapy cannot be used as a substitute for 14‐day therapy. Vonoprazan exerted excellent gastric acid suppression during eradication. Trial Registration Chinese Clinical Trial Registry: ChiCTR2200057625

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsAmoxicillinPyrrolesSulfonamidesAnti-Bacterial AgentsProton Pump InhibitorsHumansMaleFemaleMiddle AgedAdultHelicobacter pyloriTreatment OutcomeAgedDrug Therapy, CombinationHydrogen-Ion Concentration

Stichwörter der Autor:innen

Helicobacter pyloridual therapydurationgastric acid suppressionvonoprazan

Substanzen

Amoxicillin1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamidesAnti-Bacterial AgentsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
  • Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Gastroenterology, Qinghai University Affiliated Hospital, Xining, Qinghai, China.
  • Department of Gastroenterology, Wenchang People's Hospital, Wenchang, Hainan, China.
  • Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Zhiqiang Song, Xiuli Zuo, Zhenyu Zhang, Yueyue Li, Liya Zhou

Förderung

  • Key laboratory for Helicobacter pylori infection and upper gastrointestinal diseases in Beijing
  • Takeda Pharmaceutical Company Limited, Osaka, Japan

Zitieren

APA

Song, Z., Zuo, X., Zhang, Z., Wang, X., Lin, Y., Li, Y., Xu, X., Huang, Y., Wang, Q., Shi, Y., & Zhou, L. (2025). Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. https://doi.org/10.1111/hel.70070

Vancouver

Song Z, Zuo X, Zhang Z, Wang X, Lin Y, Li Y, et al. Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. 2025. doi:10.1111/hel.70070

BibTeX
@article{Song2025,
  author = {Song, Zhiqiang and Zuo, Xiuli and Zhang, Zhenyu and Wang, Xuehong and Lin, Ya and Li, Yueyue and Xu, Xiaojun and Huang, Yun and Wang, Qiuyan and Shi, Yanyan and Zhou, Liya},
  title = {Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial},
  journal = {Helicobacter},
  year = {2025},
  doi = {10.1111/hel.70070}
}
Kostenlos starten →